ZEOX

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company specializing in developing biological therapeutics aimed at treating degenerative diseases and fostering regenerative medicine. Its flagship investigational product, Zofin, is an acellular biologic therapy sourced from perinatal materials. This candidate is currently in Phase I/II clinical trials, evaluating its efficacy for COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis. The company's portfolio also includes Patient Pure X, an autologous, blood-derived biologic technology designed to enhance the body's natural capacity to reduce cellular inflammation and promote tissue healing. Furthermore, Zeo ScientifiX develops and distributes products containing its proprietary ingredients for topical aesthetic applications. These offerings include ZEO GROW X, a professional-grade formula delivering concentrated topical exosomes to support follicular function, as well as ZEO GROW BOOST and EXO FOLLICLE FUEL. Founded in 2011, the company was formerly known as Organicell Regenerative Medicine, Inc. before rebranding to Zeo ScientifiX, Inc. in February 2024. It is headquartered in Davie, Florida.